Ekso Bionics (NASDAQ:EKSO) Share Price Crosses Above 50-Day Moving Average – Here’s What Happened

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) shares crossed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $4.77 and traded as high as $5.15. Ekso Bionics shares last traded at $4.99, with a volume of 38,611 shares.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Ekso Bionics in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $562.50.

Ekso Bionics Price Performance

The company has a 50-day moving average of $4.77 and a 200-day moving average of $16.88. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.57 and a current ratio of 1.66. The stock has a market cap of $13.09 million, a price-to-earnings ratio of -0.88 and a beta of 1.08.

Ekso Bionics (NASDAQ:EKSO) last announced its earnings results on Tuesday, October 28th. The company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.99) by $0.45. Ekso Bionics had a negative return on equity of 90.71% and a negative net margin of 70.74%.The company had revenue of $4.23 million for the quarter, compared to the consensus estimate of $4.16 million. As a group, equities research analysts predict that Ekso Bionics Holdings, Inc. will post -0.48 earnings per share for the current year.

Institutional Trading of Ekso Bionics

A hedge fund recently raised its stake in Ekso Bionics stock. Armistice Capital LLC grew its position in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 18.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,042,382 shares of the company’s stock after acquiring an additional 316,733 shares during the period. Armistice Capital LLC owned about 7.03% of Ekso Bionics worth $823,000 at the end of the most recent quarter. Institutional investors own 6.42% of the company’s stock.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.